Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Breast cancer research and treatment·2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Breast cancer research and treatment·2017